Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Industry, Sector and Symbol
Industry Private households
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:HKMPF
CUSIPN/A
Phone44-20-7399-2760
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio18.00
Forward P/E Ratio20.32
P/E Growth6.81
Sales & Book Value
Annual Sales$1.94 billion
Price / Sales2.35
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees8,500
Outstanding Shares240,870,000
Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions
What is Hikma Pharmaceuticals' stock symbol?
Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."
When is Hikma Pharmaceuticals' next earnings date?
Who are some of Hikma Pharmaceuticals' key competitors?
Some companies that are related to Hikma Pharmaceuticals include KUEHNE & NAGEL/ADR (KHNGY), SECOM Ltd/ADR (SOMLY), ThyssenKrupp (TYEKF), Deutsche Wohnen (DWHHF), thyssenkrupp (TKAMY), FERROVIAL S A/ADR (FRRVY), WILMAR Intl Ltd/ADR (WLMIY), ASHTEAD Grp PLC/ADR (ASHTY), AISIN SEIKI Co/ADR (ASEKY), AGRICULTURAL Bk/ADR (ACGBY), MTN Grp Ltd/S (MTNOY), SWATCH Grp AG/ADR (SWGAY), A P MOLLER-MAER/ADR (AMKBY), Std Lf PLC/ADR (SLFPY) and VESTAS WIND Sys/ADR (VWDRY).
Who are Hikma Pharmaceuticals' key executives?
Hikma Pharmaceuticals' management team includes the folowing people:
- Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
- Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
- Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
- Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
- Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D
Has Hikma Pharmaceuticals been receiving favorable news coverage?
Media coverage about HKMPF stock has trended somewhat positive on Friday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hikma Pharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also assigned news articles about the company an impact score of 45.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Hikma Pharmaceuticals?
Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hikma Pharmaceuticals' stock price today?
One share of HKMPF stock can currently be purchased for approximately $18.90.
How big of a company is Hikma Pharmaceuticals?
Hikma Pharmaceuticals has a market capitalization of $4.55 billion and generates $1.94 billion in revenue each year. Hikma Pharmaceuticals employs 8,500 workers across the globe.
How can I contact Hikma Pharmaceuticals?
Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected]
MarketBeat Community Rating for Hikma Pharmaceuticals (HKMPF)
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HKMPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HKMPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
